Tricyclic Compound Partial Agonist for Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PPAR γ agonists, such as thiazolidinedione derivatives, often cause side effects like body weight gain and adipocyte accumulation, and there is a need for a compound with superior hypotensive action and reduced side effects for treating conditions like type 2 diabetes, insulin resistance, hypertension, and inflammatory diseases.
Innovation Solution
A novel tricyclic compound with PPAR γ agonist activity, represented by a specific general formula, which serves as a therapeutic and/or prophylactic agent for various diseases, including type 2 diabetes, insulin resistance syndrome, hypertension, and inflammatory diseases, without the side effects of existing full agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full agonists (thiazolidinedione derivatives) are used to activate PPAR γ for treating diabetes and metabolic disorders, then therapeutic efficacy is improved, but body weight gain and adipocyte accumulation occur as side effects
Solution Approach 1:
The patent applies partial agonism principle by designing compounds that partially activate PPAR γ rather than fully activating it. The general formula (I) compounds provide sufficient therapeutic benefit for diabetes and metabolic disorders while avoiding the excessive activation that leads to unwanted adipocyte differentiation and weight gain. This is achieved by optimizing the molecular structure to achieve selective partial agonist activity.
Solution Approach 2:
The patent employs local quality principle by modifying specific regions of the tricyclic compound structure (positions R1-R20, A-D rings) to achieve differential activation of PPAR γ. The structural modifications at specific locations allow the compound to interact selectively with the receptor to produce therapeutic effects without triggering the pathological responses associated with full agonism.
2Reliability
If existing PPAR γ agonists are used for treating hypertension, then blood pressure control is achieved, but side effects like weight gain limit their use
Solution Approach 1:
The patent applies partial agonism to achieve blood pressure control without excessive weight gain. The compounds of formula (I) provide adequate PPAR γ activation for antihypertensive effect while the partial agonist profile prevents excessive adipocyte accumulation that would lead to weight gain.
3Object-generated harmful factors
If selective partial agonists are used to avoid side effects, then body weight increase and adipocyte accumulation are reduced, but hypotensive action may be compromised
Solution Approach 1:
The patent employs parameter changes by systematically varying the molecular structure parameters (substituents at R1-R20 positions, ring systems A-D, linkers) to optimize the balance between partial agonist activity and hypotensive efficacy. The structural modifications allow tuning of the compound's potency and selectivity to achieve sufficient blood pressure control while maintaining the partial agonist profile that avoids weight gain.
Data Source
AI summary
Provided is a tricyclic compound having a PPAR yagonist activity, which is represented by the general formula (I) as defined herein, or a pharmaceutically acceptable salt thereof or the like: